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doi:10.1016/j.jmii.2011.12.010Background: Recently, the proportion of adolescents diagnosed with human immunodeficiency
virus (HIV) and acquired immunodeficiency syndrome (AIDS) has increased. The aim of this
study is to evaluate the clinical and laboratory characteristics of HIV-infected adolescents in
southern Taiwan.
Methods: From June 1997 to December 2010, a total of 40 HIV-infected adolescents who sought
medical care in a university hospital in southern Taiwan were enrolled in the study. They were
classified into three HIV at-risk groups, men who have sex with men (MSM), heterosexuals, and
intravenous drug users (IDUs). Clinical and laboratory data were obtained from medical
records.
Results: The median age of the 40 HIV-infected adolescents was 19 years. The HIV at-risk
groups were MSM (22/40, 55%), heterosexuals (7/40, 17.5%), IDUs (5/40, 12.5%), and unknown
(6/40, 15%). The initial median CD4 count and log plasma HIV viral load were 318 cells/mm3
and 4.61, respectively. The seroprevalence of anti-HAV, anti-HBc, anti-HCV antibodies and
HBsAg was 5.3%, 26.1%, 13% and 13%, respectively. Among 17 adolescents who had regular
follow-ups more than twice, 7 (41.2%) had a concurrent sexually transmitted disease (STD).
The most common STD was genital warts (41.2%) followed by syphilis (11.8%). Among 7 patientsof Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung
inan City, 704 Taiwan.
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330 K.-H. Lee et al.who received highly active antiretroviral agents (HAART) for more than 12 months, 5 (71.4%)
had sustained virologic suppression.
Conclusion: MSM are the largest risk group in HIV-infected adolescents in southern Taiwan and
are characterized by a high prevalence of anogenital warts and low seroprevalence of
anti-HAV.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
It is estimated that 33.3 million people are living with
human immunodeficiency virus (HIV) globally, with nearly
2.6 million new HIV infections and 1.8 million acquired
immunodeficiency syndrome (AIDS) deaths in 2009 alone.1
In the United States, the number of cases of HIV infection
is increasing among adolescents. The Centers for Disease
Control and Prevention (CDC) reported 579 cases in 1994
and 5400 cases in 2006.2,3 From 1997 to 2006, AIDS rates
doubled in males between 15 and 24 years of age largely
due to the dramatic increase in HIV infection among males
who have sex with men in this age group.4
InTaiwan, reports have indicated that a significantnumber
of teenagers had their first sexual experiencewithout the use
ofa condomandwithmultiplepartners.5A surveyof8541high
school students inTaiwan in2000 showedthat 14%ofmaleand
10% of female students have had a sexual experience.6
Another study from 2002 and 2003 showed that 27% of
high school students in southern Taiwan have had
a sexual experience and that 79% had engaged in high-
risk sexual behavior. Among sexually active students,
8.8% had chlamydial infection and 1.1% had gonococcal
infection.7 As a result, a high prevalence of risky
behavior among teenagers has created a potential
epidemic of sexually transmitted disease (STD) and HIV.
The proportion of HIV-infected youth aged 15-24 years is
increasing from 14% (272 cases) in 2007 to 20% (351 cases) in
2009, and 28% (413 cases) in 2009 with most (90%) acquiring
HIV infection through sexual behavior.8 However, a study
evaluating the clinical profile of adolescents infected with
HIV through horizontal transmission was lacking in Taiwan.
The objective of this study is to evaluate the clinical and
immunologic characteristics, serology of viral hepatitis,
concurrent STDs, and therapeutic response to antiretroviral
agents among HIV-infected adolescents younger than 20
years old in southern Taiwan.
Materials and methods
Patient enrollment
From Jan. 1, 1997 to Dec. 31, 2010 a total of 40 HIV-
infected adolescents were enrolled. These patients were
followed in the National Cheng Kung University Hospital,
a tertiary care center in southern Taiwan. They were
categorized into three at-risk groups according to presumed
HIV transmission routes: men who have sex with men
(MSM), heterosexuals, and intravenous drug users (IDUs). All
of the data was obtained by reviewing medical records.Definitions
The age of enrollmentwas defined as the age of HIV infection
confirmedbyWesternblotmethod. Adolescence is definedas
the age between 10-19 years of age according to the World
Health Organization (WHO). AIDS was diagnosed by
a confirmed HIV-1 infection with either a CD4 cell count less
than 200 cells/mm3 or a suspected or confirmed opportu-
nistic infection or AIDS-defining malignancy. Acute HIV
infection, or primary HIV infection,was defined as the period
from the initial infection with HIV to complete seroconver-
sion. The categories of HIV surveillance such asmandatory or
active HIV testing (i.e. voluntary, anonymous HIV testing)
were defined by the policy for HIV surveillance of CDC
Taiwan.9 The clinical staging of HIV/AIDS was determined
using the revised World Health Organization (WHO) clinical
staging based on HIV-associated symptoms; asymptomatic
for stage 1, mild symptoms for stage 2, advanced symptoms
for stage 3, and severe symptoms for stage 4.10 Highly active
anti-retroviral therapy (HAART) was defined as an anti-
retroviral regimen consisting of two nucleoside reverse
transcriptase inhibitors (NRTI) combined with another NRTI
or one to twoprotease inhibitors. UndetectableHIV-1 plasma
viral load was defined as plasma HIV-1 RNA < 400 copies/
mm3. An adequate CD4 response is defined as an increase in
CD4 count in the range of 50-150 cells/mm3 per year.
Rebound of plasma HIV viral load (HIV PVL) was defined as
detectable HIV PVL above 400 copies of HIV-1 RNA/mm3 from
previous virologic suppression.
Study design
Algorithm of the study design is illustrated in Fig. 1 where
demographics and data regarding HIV surveillance are
described for all enrolled patients. Immunologic, clinical
characteristics, and seroprevalence of hepatitis A, B, and C
viruses were obtained from 24 (60%) patients who had CD4
count data soon after diagnosis. Concurrent STDs were
evaluated for 17 adolescents who attended follow-ups 2 or
more times in outpatient clinics. Immunologic and virologic
responses to HAART were analyzed among 5 chronic HIV
infection patients who received HAART strictly for more
than 12 months with sustained virologic suppression
throughout the study period.
Laboratory monitoring
We monitored complete blood cells (CBC), lymphocyte
subsets, plasma HIV RNA quantification, and serologic
testing for viral hepatitis and syphilis. Lymphocyte subsets
Figure 1. Flow chart of study design.
HIV infections in adolescents 331of CD4þ T cells, and CD8þ T cells were enumerated using
direct immunofluorescence with fluorescein isothiocyanate.
Samples were analyzed by flow cytometry (Beck-Dickinson
Immunocytometry Systems or EPICS-XL; Beckman Coulter,
CA, USA). Anti-HIV antibody was detected using an enzyme-
linked immunosorbent assay. Plasma HIV-1 RNA quantifica-
tion was assessed every three to six months in patients
receiving antiretroviral therapy. HIV-PCR was analyzedTable 1 Demographic features and human immunodeficiency v
Demographic data Total MSM
(n Z 40) (n Z
no. (%) no. (
Age (y)
16 2 (5) 1 (4.
17 9 (22.5) 4 (18
18 9 (22.5) 6 (27
19 20 (50) 11 (5
Men 36 (90) 22 (1
Married 2 (5) 1 (4.
HIV surveillance & screening
Detected by clinician 5 (12.5) 5 (22
Mandatory HIV testing 20 (50) 7 (31
Voluntary or anonymous HIV testing 10 (25) 7 (31
Unknown 5 (12.5) 3 (13
a All five cases had symptomatic HIV infection, including; one with r
with genital/oral ulcers and significant body weight loss, one with wa
b Three cases were detected by blood donation, three by military H
c Two cases were detected by blood donation, one was detected by
house.
d Three cases were detected in a drug rehab/detection center and
e One case received HIV testing because his partner was HIV positive
and two cases had a positive syphilis screening result.
* P value <0.05.
HIV Z human immunodeficiency virus; IDUs Z intravenous drug userusing primers detecting LTR-gag, pol, and env. Plasma HIV-1
RNA quantification was performed using quantitative
reverse transcriptase-PCR assay (Roche Amplicor, Version
1.5; Roche, Branchburg, NJ, USA or Cobas AmpliPrep/Cobas
TaqMan [CAP/CTM] assay). Serologic specimens were tested
for IgG antibodies to Hepatitis A Virus (HAV) (HAV-IgG)
(Axesbaden-Delkenheim, Germany), hepatitis B surface
antigen (HBsAg), antibody to HBsAg (HBsAb) (AxSYM HAVAB
2.0; Abbott GmbH Diagnostika,Wiesbaden-Delkenheim,
German), and antibodies to Hepatitis C Virus (HCV) (HCV
Ab) (AxSYM HCV version 3.0; Abbott Laboratories, Abbot
Park, IL, USA). Nontreponemal antibodies against Trepo-
nema pallidum were measured using the RPR Card Test
(Becton-Dickinson, Maryland, USA), and treponemal-
specific antibodies were measured using the T pallidum
hemagglutination (TPHA) assay (SERODIA-TPPA; Fujirebio,
Taoyuan, Taiwan). The RPR and TPHA tests were performed
according to the manufacture’s instructions. Participant
with a TPHA titer  1:160 were considered T pallidum-
seroreactive.
Statistical analysis
All statistical analyses were conducted using the Statistical
Package for the Social Sciences (SPSS) version 10.0 for
Windows (SPSS Inc, Chicago IL, USA). Data were analyzed to
determine the statistical significance of differences
between the types of HIV surveyed, the seroprevalence of
viral hepatitis and concurrent STDs among the three at-risk
groups. A p value <0.05 was considered statistically
significant.irus (HIV) surveillance among 40 HIV-infected adolescents
Heterosexuals IDUs Unknown risk
22) (n Z 7) (n Z 5) (n Z 6)
%) no. (%) no. (%) no. (%)
5) 1 (14.3) 0 0
.2) 3 (42.9) 1 (20) 1 (16.7)
.3) 1 (14.3) 0 2 (33.3)
0) 2 (28.6) 4 (80) 3 (50)
00) 5 (71.4) 4 (80) 5 (83.3)
5) 0 0 1 (16.7)
.7)a 0 0 0
.8)b* 4 (57.1)c 5 (100)d* 4 (66.7)
.8)e 3 (42.9) 0 0
.6) 0 0 2 (33.3)
ecurrent oral thrush, one with mononucleosis-like symptoms, one
sting syndrome, and one with bilateral pneumonia.
IV testing, and one in a juvenile detection house.
military HIV testing, and one was detected in juvenile detection
two cases were detected by military HIV testing.
, one case received HIV testing because his partner had syphilis,
s; MSM Z men who have sex with men.
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HIV surveillance and demographic data
During the 14 year study period, 1127 HIV-infected patients
sought HIV care at this hospital and 40 (3.6%) were HIV-
infected adolescents. The HIV at-risk groups included MSM
(22/40, 55%), heterosexuals (7/40, 17.5%), IDUs (5/40,
12.5%), and unknown risk (6/40, 15%). There were 5 (12.5%)
patients with HIV detected by their clinician due to
presentation of symptoms, 20 (50%) that were screened by
mandatory HIV testing, 10 (25%) that received voluntary or
anonymous HIV testing, and 5 (12.5%) that were unknown.
The HIV surveillance and demographic data of HIV-infected
adolescents is summarized in Table 1. The median age at
enrollment was 19.0 years (range, 16.1 to 19.9 years) with
a male-to-female ratio of 9. Two patients (5%) were
married before enrollment. All of the IDUs were screened
positive through mandatory HIV testing (p < 0.05). Data for
high-risk behaviors were available for 10 MSM and 2
heterosexual patients. The median period of high risk
behavior before HIV diagnosis was 1.4 years (range, 0.1-3.0
years) among HIV-infected adolescents.
Clinical and immunologic status
A total of 24 adolescents had recorded CD4 cell counts on
their first visit. The median CD4 count was 318 cells/mm3
(range, 11-993 cells/mm3), CD8 count was 1262 cells/mm3
(range, 177-3516 cells/mm3), and log HIV-1 viral load was
4.61 (range, 3.11-7.00). The data are summarized in
Table 2. Among 22 patients with chronic HIV infectionTable 2 Comparison of initial diagnosis, immunologic and HIV-1
infected adolescents
Categories Total
(n Z 24
no. (%)
Initial diagnosis in our hospital
Acute HIV infection 2 (8.3)
Non-AIDSa 17 (70.8
AIDSb 5 (20.8)
Immunologic data
Median CD8 cells/mm3 (range) 1262 (17
Median CD4 cells/mm3 (range) 318 (11-
Range of CD4 count cells/mm3
>350 10 (41.7
200e350 8 (33.3)
100e199 3 (12.5)
<100 3 (12.5)
Median plasma HIV RNA log 10 copies/mm3 (range) 4.61 (3.1
a Non-AIDS was defined as chronic HIV infection with CD4 count >20
were in clinical stage 1 according to revised WHO clinical staging of H
b Of the five adolescents diagnosed with AIDS, two were in clinical s
cells/mm3, one was in clinical stage 3 with and initial CD4 count of 46 c
of cells/mm3.
AIDS Z acquired immunodeficiency syndrome; HIV Z human immunowith/without AIDS, 19 (86.4%) were stage 1 and they were
either asymptomatic or had generalized lymphadenopathy.
One 19-year-old MSM (4.5%) with recurrent oral candidiasis
and ulceration was stage 2 and he was referred to the
infectious outpatient department by his dentist where 3
concurrent STDs (Syphilis, genital wart and gonorrhea)
were detected on his first visit. One 19.5-year-old MSM
(4.5%) with significant weight loss (>10%), genital ulcers
and oral candidiasis was stage 3 and concurrent genital
warts were detected during his first visit. One 17.5-year-old
MSM (4.5%) who presented with HIV wasting syndrome
and Cryptococcus sepsis was stage 4, he had significant
cachexia on his first visit to the emergency room and fol-
lowed a rapid fatal course in the second day after visiting
the hospital.
Seroprevalence of viral hepatitis
Among the 24 patients who had CD4 count data soon after
enrollment and before reaching 20 years old, the sero-
positive rate of HAV-IgG was 5.3%, HBsAg 13.0%, anti-HBc
26.1% and HCV Ab 13.0% (Table 3). For patients born after
Jul 1984 (n Z 18), two patients (11.1%) were seropositive
for HBsAg and five (27.8%) were seropositive for anti-HBc
antibody.
Concurrent STDs
Among the17 patients (13 MSMs and 4 heterosexuals) who
received continuous follow-up 2 times in the cohort, none
of heterosexuals had concurrent STD. The rates of
concurrent STDs among MSM group were 53.8% (Table 4).viral load data among human immunodeficiency virus (HIV)-
MSM Heterosexuals IDUs
) (n Z 17) (n Z 6) (n Z 1)
no. (%) no. (%) no. (%)
2 (11.8) 0 0
) 11 (64.7) 5 (83.3) 1 (100)
4 (23.5) 1 (16.7) 0
7e3516) 1245 (177e3516) 1280 (716e1402) 915
e993) 288 (11e941) 549 (151e993) 586
) 5 (29.4) 4 (66.7) 1 (100)
7 (41.2) 1 (16.7) 0
2 (11.8) 1 (16.7) 0
3 (17.6) 0 0
1e7.00) 4.64 (3.11e7.00) 3.88 (3.57e5.30) 3.68
0 without AIDS defined illness. All 17 of the non-AIDS adolescents
IV/AIDS for adults and adolescents.10
tage 1, one was in clinical stage 2 with an initial CD4 count of 152
ells/mm3, and one was in clinical stage 4 with an initial CD4 count
deficiency virus; MSM Z men have sex with men.
Table 3 Seroprevalence of viral hepatitis among human immunodeficiency virus (HIV)-infected adolescents
Serologic test All tested MSM Heterosexual IDUs
Case no. with positive result/case no. tested (%)
HAV-IgG 1/19 (5.3) 0/14 (0) 1/4 (25) 0/1 (0)
HBsAg 3/23 (13.0)a 1/16 (6.3) 2/6 (33.3) 0/1 (0)
HBc Ab 6/23 (26.1)b 2/16 (12.5) 4/6 (66.7) 0/1 (0)
HCV Ab 3/23 (13.0) 1/16 (6.3) 1/6 (16.7) 1/1 (100)
a Of the three patients who were seropositive for HBsAg, one was born in July 1981, one in May 1985, one in November 1990. The HBsAg
seropositive rate among those born after July 1984 was 11.1%.
b The HBc Ab seropositive rate among those born after July 1984 was 27.8%.
HAVZ hepatitis A virus; HBc AbZ anti-hepatitis B core protein antibody; HBsAgZ hepatitis B surface antigen; HCV AbZ anti-hepatitis
C virus antibody; HIV Z human immunodeficiency virus; IDUs Z intravenous drug users; IgGZ immunoglobin G; MSM Z men who have
sex with men.
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There were 13 patients that received HAART therapy during
the study period in our cohort. Of them, 7 cases were
treated for more than 12 months, two (28.6%) of which
experienced virologic failure. One patient was tracked
beginning in the 8th month of HAART for 26 months. Another
patient had a temporary rebound of HIV PVL in the 20th,
36th, and 46th month with 5750, 2240, and 440 copies of
HIV RNA/mm3 during 112 months, respectively. Of the 5
(71.4%) patients that had sustained virologic suppression
throughout the study period, the median duration of HAART
treatment was 20 months (range, 14-70 months). The
immunologic and virologic responses were summarized in
Table 5.
Outcome
Among 24 patients with available CD4 counts, 2 (8.3%) died
soon after visiting the hospital. One AIDS patient died ofTable 4 Sexually transmitted diseases among human
immunodeficiency virus (HIV)-infected adolescents who
received continuous follow-ups 2 times at a tertiary care
hospital
Reported sexually
transmitted diseases
(STDs)
Total MSM Heterosexuals
(n Z 17) (n Z 13) (n Z 4)
no. (%) no. (%) no. (%)
Syphilisa 2 (11.8) 2 (15.4) 0
Genital warts 7 (41.2) 7 (53.8) 0
Genital herpes 1 (5.9) 1 (7.7) 0
Gonorrhea 1 (5.9) 1 (7.7) 0
Any concurrent STDs 7 (41.2) 7 (53.8) 0
Concurrent STDs, no.
1 STD 2 (11.8) 3 (23.1) 0
2 STDs 5 (29.4) 4 (30.8) 0
a Serum rapid plasma regain (RPR) titers 1:4 among patients
with Treponema pallidum hemagglutination (TPHA) titer 1:160.
HIVZ human immunodeficiency virus; MSMZmen have sex with
men; RPR Z rapid plasma regain; STDs Z sexually transmitted
diseases; TPHA Z Treponema pallidum hemagglutination.AIDS wasting syndrome and Cryptococcus sepsis with an
initial CD4 count of 38 cells/mm3 during the 2nd day of
hospitalization. Another patient with acute HIV infection
died of severe influenza pneumonia with an initial CD4
count of 11 cell/mm3 in the 10th day of hospitalization. Of
the 17 patients with regular follow-ups, 1 (5.9%) MSM had
newly acquired syphilis 20 months after enrollment. Of the
13 patients who received HAART, all survived with a median
of 14 months for HAART therapy (range 1-112 months)
without new opportunistic infections or HIV associated end
organ damage.Discussion
HIV-1 infection in pediatric patients causes a broad spec-
trum of disease by various transmitted routes. Most pedi-
atric HIV infections are acquired through mother-to-child
transmission, although infection via contaminated blood
products or tissue, unsafe injection or incision practices,
and sexual abuse also takes place.11 In adolescents, hori-
zontal spread of transmission through sexual contact and
intravenous drug use are substantial methods of trans-
mission. Adolescents must be an important focus for HIV
prevention programming and research. In Taiwan, adoles-
cents aged 10-19 years old make up a small percentage
(1.8%, 338/19105) of HIV-infected patients during our
study period (1997-2010) according to statistics from CDC
Taiwan.12 Most of our 40 cases have behavioral acquisition
of HIV-1 infection and half of them were screened by
mandatory HIV testing.
The rate of HIV progression varies widely among individ-
uals, the median time of progression from HIV infection to
AIDS is nine to ten years.13 In the current study, about one-
fifth (20.8%) of adolescents diagnosed with AIDS experi-
ence amedian 2 year period of engaging in high risk behavior
at enrollment. Rapid HIV progression may be related to
immunologic variation of susceptible host and genetic vari-
ation of infective virus.14 However, studies of rapid HIV
progression among sexually active youth is lacking.
In Taiwan, HIV-positive MSM, heterosexuals, and IDUs all
had significant higher prevalence of anti-HAV antibodies
compared with HIV-negative persons. Increasing age was
also associated with increased anti-HAV antibody preva-
lence.15 Young age may account for the low HAV seroposi-
tivity because only one patient (5.3%) was positive for
Table 5 Treatment response among five human immunodeficiency virus (HIV)-infected adolescents who received highly active
antiretroviral agents (HAART) strictly for 12 months with sustained virologic suppression throughout the study period
Case 1 Case 2 Case 3 Case 4 Case 5
Enrollment year 2005 2005 2006 2009 2009
Gender Male Male Male Male Male
Age (y) 19.9 19.3 19.2 17.9 19.5
Period from enrollment to HAART (mo) 0.4 37 35 0.4 0.2
CD4þ cell count prior to HAART (cells/mm3) 205 305 365 151 46
PVL prior to HAART (log10 copies/mm3) 5.95 4.87 4.35 3.7 5.12
Duration of HAART treatment (mo) 70 25 14 15 20
Treatment response
Time to undetectable HIV PVL (mo) 1.4 3.3 1.2 0.9 4
Increased CD4 count after 6 months of therapy (cells/mm3) 403 165 316 188 110
Increased CD4 count after 12 months of therapy (cells/mm3) 565 74 287 461 201
Increased CD4 count per year (cells/mm3/y) 121 51 239 192 189
CD4 count at the end of follow-up(cells/mm3) 920 413 652 400 367
HAART Z highly active antiretroviral therapy; HIV Z human immunodeficiency virus; PVL Z plasma viral load.
334 K.-H. Lee et al.anti-HAV in our study. This low prevalence of HAV infection
also makes HIV-infected adolescents optimal candidates
for HAV vaccination. Current guidelines also recommend
HAV vaccination as an important preventive strategy for
HIV-infected MSMs, IDUs and persons with chronic liver
disease or co-infected with hepatitis B and/or C.16 Studies
also reveal that HAV vaccination could induce durable
seropositive responses up to 6-10 years among HIV-infected
adults and could induce high immune response in HIV-
infected children aged 2-16 years.17,18
Hepatitis B virus is one of the major causes of chronic
liver disease in Taiwan. 18 of 23 (78.3%) tested adolescents
in our study were born after July 1984 when the nationwide
Hepatitis B Vaccine (HBV) vaccination program was
launched. This mass vaccination program for infants
provides not only long-term protection from Hepatitis B for
up to 20 years but also a reduction of HBV infection in
Taiwan.19 Recent studies have shown significant decline in
the seroprevalence of HBV infection among both HIV-
negative and HIV-positive persons who were born in the
era of nationwide HBV vaccination in Taiwan and the
seroprevalence of HBsAg and anti-HBc among HIV-infected
patients born after Jul 1984 was 3.3% and 30.0% respec-
tively.20 Among our patients born after July 1984, a similar
seropositive rate of anti-HBc (27.8%, 5/18) and higher
seropositive rate of HBsAg (11.1%, 2/18) are observed. In
the general population, the seroprevalence of HBsAg and
anti-HBc antibody was 1.6% and 4.1% in those born after
July 1986 in adolescents aged 15-17 years in Taiwan.21
Because high risk behaviors increase the exposure to HBV
and because subclinical infection could happen, it is
reasonable that seroprevalence of anti-HBc antibody is high
among HIV-infected patients born after July 1984. As for
the 2 cases born after July 1984 with positive HBsAg, HBV
breakthrough infection or natural HBV infection is hard to
conclude due to a lack of HBV vaccination information.
However, HBV infection was truly a concern among sexually
active HIV-infected adolescents because 10.1% of the
general population may have lost immune memory to
hepatitis B antigen when they were 15-18 years old.21Booster of hepatitis B vaccine should be considered in
those high risk groups with negative HBs antibody.
Concurrent STDs in HIV infected persons are common. In
southern Taiwan, reports have shown that the prevalence
of STDs before and at the diagnosis of HIV to be approxi-
mately 40% (syphilis 38% and genital warts 14%).22 Our study
reports a similar prevalence of concurrent STDs (41.2%)
and the most common STD being genital warts (53.8%)
instead of syphilis (15.4%) among MSM. For Human Papil-
loma Virus (HPV) infection, recent studies demonstrated
that younger age was independently associated with
detection of anal HPV in HIV-negative MSM. The prevalence
of HPV infection among MSM aged 18-24 years is high (60%)
and decreases gradually with increasing age.23,24 Persons
who are HIV-infected are more likely to develop genital
warts than persons who are not HIV-infected.25 As a result,
HPV infection may become an important issue among
HIV-infected young homosexuals.
Virologic response to HAART treatment of HIV infection
depends on viral sensitivity to antiretrovirals and medica-
tion adherence. As previous studies indicate, medicine
adherence rates among HIV-infected youth are poor with
the rate of adherence ranging from 28.3% to 69.8%.26,27
Among our patients who received an antiretroviral agent
for more than 12 months (n Z 7), most (71.4%) had
sustained virologic suppression, suggesting that the
majority of our patients have good adherence to medica-
tion but further investigation is needed to elucidate the
phenomena. Because adolescence is a period that is
characterized by rapid changes in physical maturation,
cognitive processes, and life style, predicting long-term
adherence in an adolescent can be very challenging.
In response to the increasing proportion of youth people
infected with HIV in Taiwan, risk-reduction strategies for
preventing sexually transmitted acquisition of HIV among
adolescents should be developed by social, behavioral and
public health experts. A recent study concluded that
behavioral interventions reduced adolescent risk for STDs
more broadly, increase condom use, reduce or delay
frequency of penetrative sex, and increase skills to
HIV infections in adolescents 335negotiate safer sex and to acquire condoms.28 More
accessible HIV testing, HIV counseling, and behavior inter-
ventions are important for awareness of HIV-infected status
and for decreasing HIV transmission among HIV-infected
people.29
Our study has several limitations. First, it is a retro-
spective observational study; we were not able to assess
the data regarding psychosocial issues like mental illness,
substance abuse, family and financial support, and devel-
opmental problems among our patients because of limited
data on medical records. Second, statistical analysis of
STDs among at-risk groups could not be performed because
of a limited number of patients. Third, evaluation of long-
term immunologic response to HAART and HIV-associated
morbidity among these adolescents is incomplete due to
a lack of long term follow-up. This study, though the case
number is small, is the first study focused on the clinical
and laboratory characteristics among HIV-infected adoles-
cents in Taiwan.
In conclusion, adolescent-oriented HIV health care could
be developed owing to the unique clinical characteristics of
HIV infection in this group. A high prevalence of sexually
transmitted diseases such as anogenital warts among men
who have sex with men are similar to reports in Western
countries. Considering the global trend of increasing
numbers of youth infected with HIV, more effort should be
taken for prevention and harm-reduction policy among
adolescents with HIV infection in Taiwan.
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